AUROBINDO PHARMA LTD. - 524804 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board meeting held on 9th November 202309-11-2023
09-11-2023
AUROBINDO PHARMA LTD. - 524804 - Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Intimation of November 20, 2023 as Record Date for payment of Interim Dividend for FY 2023-24, if declared.02-11-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Call to be held on November 10, 2023, at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.31-10-2023
AUROBINDO PHARMA LTD. - 524804 - Board Meeting Intimation for Intimation Of Board Meeting.
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, November 9, 2023, to consider and approve inter alia, the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, and 2. payment of Interim Dividend, if any, for the financial year 2023-24.27-10-2023
Aurobindo Pharma's arm gets FDA nod for hypogonadism drug
Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).23-10-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Eugia Pharma receives USFDA approval for Testosterone Cypionate Injection23-10-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
The Company has received the letter from following shareholder informing about the loss of share certificate and requested for issue of duplicate share certificate.19-10-2023
Aurobindo Pharma rises on launch of greenfield facility in Andhra
Aurobindo Pharma inaugurated a Rs 600 crore injectibles manufacturing unit in Visakhapatnam, Andhra Pradesh.17-10-2023
AUROBINDO PHARMA LTD. - 524804 - Inauguration Of Green-Field Manufacturing Unit Of Eugia Steriles Private Limited, A 100% Step-Down Subsidiary Of The Company.
Inauguration of green-field manufacturing unit of Eugia Steriles Private Limited a 100% step-down subsidiary of the Company.16-10-2023
AUROBINDO PHARMA LTD. - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Further to our disclosure dated September 1, 2022 informing about (i) expansion of the biologics manufacturing facilities and (ii) exploring the possibilities to enter into contract manufacturing operations (CMO) for biologicals, we further inform you that CuraTeQ Biologics Private Limited (CuraTeQ), a wholly owned subsidiary of the Company, along with its subsidiary(ies), has been in discussions with Merck Sharp & Dohme Singapore Trading Pte Ltd., and its affiliates (MSD) for CMO operations and in this regard the parties have signed a limited Letter of Intent (LOI). The parties under the said LOI intend to conclude the negotiations by March 31, 2024.11-10-2023